Mäntyjärvi M
Scand J Rheumatol. 1985;14(2):171-4. doi: 10.3109/03009748509165500.
The eyes of 63 patients, age range 28 to 79 years, affected by rheumatoid arthritis and undergoing long-term hydroxychloroquine treatment were followed from 3 to 95 months. The daily dose of hydroxychloroquine was 300 mg, and after 5 months there was a pause of one month in the treatment. The total amount of hydroxychloroquine received ranged between 27 and 630 g. In the eye examination only one patient had corneal changes, and another patient had suspected retinal damage. This is in agreement with earlier studies. Hydroxychloroquine seems to be a safe alternative among the antimalarial drugs as far as eyes are concerned.
对63例年龄在28至79岁之间、患有类风湿性关节炎且正在接受长期羟氯喹治疗的患者的眼睛进行了3至95个月的随访。羟氯喹的日剂量为300毫克,5个月后治疗中断1个月。羟氯喹的总摄入量在27至630克之间。眼部检查中只有1例患者有角膜改变,另1例患者疑似视网膜损伤。这与早期研究结果一致。就眼睛而言,羟氯喹似乎是抗疟药物中一种安全的选择。